Received Sep 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | IM |
second dose of vaccine is late; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received HAB (Twinrix) for prophylaxis. Concomitant products included HEPATITIS A VACCINE INACT;HEPATITIS B VACCINE RHBSAG (YEAST) (TWINRIX). On 03-SEP-2025, the patient received the 2nd dose of Twinrix (intramuscular) 1 ml. On 03-SEP-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: second dose of vaccine is late). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 04-SEP-2025 A patient who was transferred from the response center and had a question concerning Twinrix dose scheduling. The standard dosing schedule consists of 3 doses (1-ml each), given intramuscularly at 0, 1, and 6 months so the second dose of vaccine was late. The patient disconnected the call when asked details for filing a safety report.
TWINRIX